POSTER SESSIONS

Sunday 7th December
3.30 – 4.00pm and 5.30 – 6.30pm

Human Vaccines Infectious Disease
Abstract numbers P1 – P77

Human Vaccines Non Infectious Disease
Abstract number P78

Monday 8th December
10.30 – 11.00am, 12.30 – 1.30 and 4.00 – 4.30pm

Late Breaker
Abstract numbers P97 – P144

Other
Abstract numbers P145 – P150

Production
Abstract numbers P151 – 154

Vectors, Adjuvants, Delivery Systems
Abstract numbers P155 - P174

Tuesday 9th December
10.30 – 11.00am and 12.45 – 1.15pm

Veterinary Vaccines
Abstract numbers P175 – P192

Immunology/Animal Models
Abstract numbers P79 - P96
P1  Immunogenicity of Pneumococcal Vaccine Among elderly hospitalised patients
I Ridda¹, CR MacIntyre¹,⁵, PB McIntyre¹, ¹National Centre for Immunization Research and Surveillance, Australia, ²Discipline of Medicine: Geriatric Medicine, The University of Sydney, Australia, ³The Australian Red Cross blood services, Australia, ⁴School of Public Health and Community Medicine, The University of New South Wales, Australia, ⁵School of Public Health and Community Medicine, The University of New South Wales, Australia

P2  Vaccinal Prevention of Hepatitis B: Do “Poor” Children Benefit it as Much as “Rich” Children?
Vien NGUYEN CONG¹,², Thien CHAU PHAT¹, ¹Children's Hospital N2, Viet Nam, ²GSK Biologicals, Viet Nam

P3  Protective Cellular and Humoral Immune Responses Induced by Mucosal Vaccines Against Streptococcus pneumoniae
D. M. Ferreira¹, M. Darrieux¹, L. C. C. Leite¹, P. L. Ho¹, E. N. Miyaji¹, M. L. S. Oliveira¹, ¹Instituto Butantan, Brazil

P4  Flavitrack, a database to determine functional and immunologically important regions of Flavivirus sequences.
Petr Danecek¹, Catherine H. Schein¹, ¹University of Texas Medical Branch, United States

P5  Immunogenetic correlates of immune response to the smallpox vaccine
I.G. Ovsyannikova¹, R.M. Jacobson¹, R.A. Vierkant¹, V.S. Pankratz¹, G.A. Poland¹, ¹Mayo Clinic College of Medicine, United States

P6  Cluster of Invasive Streptococcus pneumoniae Among Adults: Reminder To Vaccinate
RJ Nett¹,², KK Carter¹,², ¹Centers for Disease Control and Prevention, United States, ²Idaho Department of Health and Welfare, United States

P7  Active Epidemiologic Surveillance of Invasive Pneumococcal Disease (IPD) and Chest Radiograph (CXR)-Confirmed Pneumonia (CXR+Pn) in Children in San José, Costa Rica
A. Arguedas¹, A. Abdelnour¹, R. Dagan², S. Gray², J. Markowitz³, G.L. Rodgers³, ¹Instituto de Atención Pediátrica, Universidad de Ciencias Médicas, Caja Costarricense de Seguro Social, Costa Rica, ²Pediatric Infectious Disease Unit, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel, ³Wyeth Pharmaceuticals, United States

P8  Intradermal Hepatitis B Vaccination in Non-responders after Topical Application of Imiquimod (Aldara) on the Vaccinated Skin
AHE Roukens¹, GJ Boland², ACTM Vossen¹, JT van Dissel¹, LG Visser¹, ¹Leiden University Medical Center, Netherlands, ²University Medical Center Utrecht, Netherlands

P9  Influenza A Virus Matrix Protein 1-Specific Human CD8+ T Cell Response Induced in Trivalent Inactivated Vaccine Recipients
M Terajima¹, J Cruz¹, AM Leporati¹, L Orphin¹, JAB Babon¹, MDT Co¹, ¹University of Massachusetts Medical School, United States

P10  SARS-CoV S Protein Induces Strong Mucosal Immune Responses and Provides Long-term Protection Against SARS-CoV Infection
BJ Zheng¹, L Du¹,², G Zhao¹, ¹Department of Microbiology, The University of Hong Kong, China, ²Lindsey F. Kimball Research Institute, The New York Blood Center, United States, ³Department of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, China, ⁴Department of Biochemistry, The University of Hong Kong, China, ⁵State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, China
P11 Epidemiologic Surveillance of Invasive Pneumococcal Disease (IPD) and Chest Radiograph (CXR)-Confirmed Pneumonia (CXR+Pn) in Children in Bogota, Colombia
J.A. Benavides¹, C. Reyes², M. Flitter³, J. Markowitz³, G.L. Rodgers³, ¹Centro Nacional de Investigación, Grupo SaludCoop, Colombia, Colombia, ²Wyeth Pharmaceuticals, Colombia, Colombia, ³Wyeth Pharmaceuticals, USA, United States

P12 Pertussis in Adults with Persistent Cough: A Prospective Follow Up Study in Primary Care, Spain
J. Puig-Barbera¹, J. Diez-Domingo², E. Pastor-Villalba³, J. García-Lomas³, I. Huertas-Zarco³, S. Pérez-Hoyos⁴, ¹Centro Salut Pública Castello, Spain, ²Valencia Vaccine Institute, Spain, ³Instituto Valenciano de Microbiología, Spain, ⁴Dirección General de Salud Pública, Spain, ⁵Escuela Valenciana Estudio de Salud, Spain

P13 An improved protocol for the synthesis of Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid conjugated antigen.
APAL Lorthiois¹, MT Takagi¹, JCC Cabrera-Crespo¹, IR Raw¹, MMT Tanizaki¹, ¹Instituto Butantan, Brazil

P14 Development of a candidate vaccine to HCV using a plant virus based adjuvant.
Christian Savard¹, Denis Leclerc¹, ¹Infectious disease research center, Canada

P15 Development of a vaccine against chlamydial STD infection and disease
P. Timms¹, K. Beagley¹, L. Hafner¹, ¹Queensland University of Technology, Australia

P16 Scheduling of Measles Vaccination Campaigns in Low-income Countries: Projections of a Dynamic Model
CT Bauch¹, E. Szusz², BW Bresnahan¹, T Hazlet¹, S Kadiyala¹, D. Veenstra¹, L. Garrison¹, ¹Department of Pharmacy, University of Washington, United States, ²Department of Mathematics and Statistics, University of Guelph, Canada

P17 Cost-effectiveness of adding new rotavirus vaccines to the national immunization program in Kyrgyzstan
E.T. Flem¹, R. Latipov²-³, Z.S. Nurmativ⁴, Y. Xue⁵, K.T. Kasymbekova⁴, R. Rheingans⁵, ¹Norwegian Institute of Public Health, Norway, ²Research Institute of Virology, Uzbekistan, ³University of Oslo, Norway, ⁴Department of State Sanitary-Epidemiologic Surveillance, Ministry of Health, Kyrgyzstan, ⁵Rollins School of Public Health, Emory University, United States

P18 Burden of Pneumococcal Disease (PD) in Eastern Europe: Importance of Inclusion of Pneumococcal Conjugate Vaccine (PCV) into National Immunization Programs (NIPs)
C. Burman¹, K.J. Center¹, D.J. Isaacman¹, ¹Wyeth Pharmaceuticals, United States

P19 Burden of Pneumococcal Disease (PD) in Latin America (LA): Importance of Inclusion of Pneumococcal Conjugate Vaccine (PCV) into National Immunization Programs (NIPs)
C.S. Garcia¹, K.J. Center¹, G.L. Rodgers¹, R.R. Reinert², R. Dagan³, A. Arguedas⁴, ¹Wyeth Pharmaceuticals, United States, ²Wyeth Research, France, ³Pediatric Infectious Disease Unit, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel, ⁴Instituto de Atención Pediátrica, Universidad de Ciencias Médicas, Costa Rica

P20 Burden of Pneumococcal Disease (PD) in the Asia-Pacific (AP) Region: Importance of Inclusion of Pneumococcal Conjugate Vaccine (PCV) into National Immunization Programs (NIPs)
C.S. Garcia¹, K.J. Center¹, G. Herrera¹, ¹Wyeth Pharmaceuticals, United States

P21 Comparison of ELISA and toxin neutralization to detect changes in immunogenicity of anthrax vaccines in mice
J.A. Castelan-Vega¹, L. Sirota², P. Parreiras², J.L. Arciniega², ¹Escuela Nacional de Ciencias Biologicas, Mexico, ²Center for Biologic Evaluation and Research, United States
B- and T-Cell-Mediated Protection Induced by Nasal Administration Using Live Attenuated Bordetella pertussis BPZE1

Pascal Feunou Feunou1, Anne-Sophie Debrée1, Julie Bertout1, Camille Locht1, Institut Pasteur de Lille, France

Hospitalisation of children with varicella in an unvaccinated population during 1998-2007

A Nilsson1, M Eriksson1, P Grimheden1, R Bennett1, Anders Hjern2, Karolinska Institutet, Sweden, National Board of Health and Welfare, Sweden

Heterologous HA DNA prime - inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses

S. Wang1, C. Parker1, J. Taffe2, A. Solórzano2, A. García-Sastre2, S. Lu1, University of Massachusetts Medical School, United States, Mount Sinai School of Medicine, United States

In Vitro Evidence that Commercial Influenza Vaccines Are Not Similar in Their Ability to Activate Human T Cell Responses

M Co1, L Orphín1, J Cruz1, P Pazoles1, F Ennis1, M Terajima1, University of Massachusetts Medical School, United States

ELVIRA A and ELVIRA B: Two Genetically Engineered Human Cell Lines Expressing Influenza Inducible Reporters for Detecting and Quantifying Influenza Virus A and B

Y Li1, T Curtiss1, D Scholl1, P Olivo1, A Pekosz2, A Larrimer1, Diagnostic Hybrids, United States, Johns Hopkins Bloomberg School of Public Health, United States

Selection of HIV-1 subtype A phage libraries for HIV preventive vaccine development

A.N. Galkin1, A.I. Soloviev1, S.M. Kiselev1, E.Y. Gagarina1, A.B. Bychenko1, E.Y. Filinova1, Advanced Biomedical Researches Laboratory, Russian Federation

Serotyping S. pneumoniae by Bio-Plex Multiplex antigen detection assay and protective spectrum of 3 different conjugated pneumococcal vaccines

M Ceyhan1, RC George2, C Sheppard4, I Yildirim1, Hacettepe University, School of Medicine, Department of Pediatric Infectious Diseases, Turkey, Respiratory & Systemic Infection Laboratory, United Kingdom

Postpartum Immunization Against Pertussis in a High-Risk Population

C.M. Healy1,2, M.A. Rench1,2, C.A. Cullinan1, L. Castagnini2, C.J. Baker1,2, Center for Vaccine Awareness and Research, Texas Children's Hospital, United States, Baylor College of Medicine, United States

Clinical impact of cholera toxin B subunit expressed rice-based vaccine(MucoRice): Crucial protective role of antigen specific secretory IgA and cross-protection against cholera toxin and E.coli heat labile enterotoxin

D.Tokuhara1, Y Yuki1, T Nochi1, S Kurokawa1, H Kiyono1, The Institute of Medical Science, The University of Tokyo, Japan

A 5- year follow-up of antibody response in children vaccinated with single dose of live attenuated SA-14-14-2 Japanese encephalitis vaccine: Immunogenicity and anamnestic responses

Jay Bahadur Tandan1, Young Mo Sohn1, Sutee Yoksan1, Min Ji1, Heechoul Ohr1, Japanese Encephalitis Support Group, Nepal, Yonsei University, College of Medicine, Department of Paediatrics, Korea, Republic of, Mahidol University, Vaccine Development Center, Thailand, Yonsei University, College of Medicine, Department of Preventive Medicine, Korea, Republic of, Yonsei University, College of Medicine, Department of Preventive Medicine, Korea, Republic of

Inactive recombinant HCV particle immunization of mice could induce antibody response

Omi Noriaki1,2, Akazawa Daisuke1,2, Takahashi Hitoshi1,2, Ishii Koji2, Suzuki Tetsuro2, Wakita Takaji2, Toray Industry, Inc., Japan, National Institute of Infectious Diseases, Japan
P33 Development of a Peptide Based Universal Influenza Vaccine
PL Smith¹, K Norgate¹, E Hegarty¹, ¹St George’s University of London, United Kingdom

P34 Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Given with Routine Pediatric Vaccination to Healthy Infants in France
E. Grimpel¹, D. Scott², F. Laudat³, S. Baker², W. Gruber², PCV13 Multicenter Study Group⁴, ¹Hôpital Armand Trousseau, France, ²Wyeth Vaccine Research, United States, ³Wyeth Vaccine Research, France, ⁴Multiple investigational sites, France

P35 Estimated Cost–Effectiveness of Heptavalent Pneumococcal Conjugated Vaccine (PCV7) in Colombian Children
M Santa Maria¹, F Garcia¹, MJ Uribe¹, ¹Economic Studies Center, FEDESARROLLO, Colombia

P36 An update of the GARDASIL® (Quadrivalent Human Papillomavirus [HPV] Vaccine) Clinical Trial Program
R.M. Haupt¹, ¹Merck Research Laboratories, United States

P37 A Universal Influenza Vaccine Using an M2e/NP Fusion Protein Linked to Immunostimulatory Sequences (ISS)
D Higgins¹, T dela Cruz¹, R Milley¹, A Hillebrand¹, C Amuel², G Van Nest¹, ¹Dynavax Technologies, United States, ²Dynavax - Europe, Germany, ³Baylor College of Medicine, United States

P38 A Novel Plasmid DNA Technology (GTU) Applied As A Potential HIV1/AIDS Therapeutic Vaccine
EV Vardas¹, C Gray², I Stanescu³, V Blazevic³, M Valtavaara³, M Leinonen⁴, ¹University of Witwatersrand, Perinatal HIV Research Unit, Soweto, South Africa, ²National Institute of Communicable Diseases, South Africa, ³FIT Biotech Plc, Finland, ⁴4 Pharma, Finland, ⁵FIT Biotech Plc, Estonia, ⁶Institute of Technology, Estonia

P39 A Randomized, Double Blind, Controlled Clinical Trial to Evaluate the Efficacy and Safety of CJ-50300, a Newly Developed Cell-Culture Derived Smallpox Vaccine in Healthy Volunteers
HC Jang¹, S Lee¹, KH Song¹, WB Park¹, M Oh¹, KW Choe¹, ¹Seoul National University, Korea, Republic of

P40 Persistence of influenza vaccine seroprotection in lung transplant patients
MS Hayney¹, JJM Moran¹, ¹University of Wisconsin School of Pharmacy, United States

P41 Modelling the benefits of vaccinating the elderly in Ontario with an intradermal influenza vaccine
S Aballéa¹, J Roiz², J Kwong², C Reygrobellet³, ¹i3 Innovus, United Kingdom, ²Institute for Clinical Evaluative Sciences, Canada, ³Sanofi Pasteur, France

P42 Alphavirus Vector-based Vaccine Development Against Argentine Hemorrhagic Fever
A.V. Seregin¹, N.E. Yun¹, S. Paessler¹, ¹University of Texas Medical Branch, United States

P43 Impact of Missed PCV7 Doses on Burden of Lower Respiratory Tract Disease in Children
S.I. Pelton¹, D. Weycker², J.O. Klein², D. Strutton³, V. Ciuryla³, G. Oster², ¹Boston University Schools of Medicine and Public Health, United States, ²Policy Analysis Inc. (PAI), United States, ³Wyeth Research, United States

P44 Public Health and Economic Impact of 7-valent Pneumococcal Conjugate Vaccination in an Influenza Pandemic in the US
J.L. Rubin¹, L.J. McGarry¹, K. Klugman², D. Strutton³, V. Ciuryla³, K. Gilmore³, ¹i3 Innovus, United States, ²Emory University, United States, ³Wyeth Research, United States

P45 Obstacles in the motivation of health care workers for pertussis vaccination
S Wicker¹, S Zielen², MA Rose², ¹University Hospital, Occupational Health Service, Germany, ²University Hospital, Children’s Hospital, Germany
P46 The Effect Of High-Dose Vitamin A Supplementation Administered With BCG Vaccine At Birth May Be Modified By Subsequent DTP Vaccination
CS Benn1, A Rodrigues2, M Yazdanbakhsh3, 1Bandim Health Project, Statens Serum Institut, Denmark, 2Bandim Health Project, Indepth Network, Guinea-Bissau, 3Department of Immunoparasitology, Leiden University Medical Centre, Netherlands, 4The MRC Laboratories, Gambia

P47 Safety and immunogenicity of an influenza vaccine A/H5N1 administered with and without a heat-labile enterotoxin (LT) patch in healthy adults
G M Glenn1, S A Frech1, J Wen1, D N Thomas1, 1Iomai Corporation, United States

P48 Diphtheria-Tetanus-Pertussis Vaccine and Child Survival in Low-Income Countries: Non-Specific and Sex-Differential Effects
P Aaby1, CS Benn1, 1Bandim Health Project, Guinea-Bissau

P49 Medical Grade Extracellular Matrix As A Novel Vaccine Adjuvant
P Hall1, M Hiles1, M Suckow2, 1Cook Biotech Inc, United States, 2University of Notre Dame, United States

P50 Desired Immune Response Characteristics In An RSV Vaccine: What Infants Tell Us
JL Reed1, L Avendano2, L Velozo3, RC Welliver, Sr4, 1Food and Drug Administration, Center for Biologics Evaluation and Research, United States, 2Programa de Virologia, Universidad de Chile, Chile, 3Unidad de Anatomía Patológica, Hospital Roberto del Río, Chile, 4Women and Children’s Hospital, United States

P51 Effective increasing the immunogenicity of a marketed Pneumococcal vaccine by addition of a nanoparticulate adjuvant, Posintro™, formulated with a protein antigen.
A Schiott1, S Manniche1, N Kirkby1, 1KMA-Rigshospital, Denmark

P52 The Immunogenicity and Efficacy of a Virus-like Particle Vaccine Candidate against Respiratory Syncytial Virus in Mice
L McGinnes1, M Murawski1, R Finberg1, E Kurt-Jones1, A Frair1, K Mahmood3, Y Wu2, P Pushkoe2, P Heaton2, T Morrison1, 1University of Massachusetts, United States, 2Novavax, United States

P53 Role of CD4+ and CD8+ T Cells in Protection against Lethal Encephalitis Mediated by a Sinbis-VEEV Chimeric Vaccine
N.E. Yun1, A.S. Bertke1, M.A. Zacks1, A.L. Poussard1, J.K. Smith1, S. Paessler1, 1University of Texas Medical Branch, United States

P54 Active Epidemiologic Surveillance of Invasive Pneumococcal Disease (IPD) and Chest Radiograph (CXR) Confirmed Pneumonia (CXR+Pn) in Children in Goiânia, Brazil
A.L.S.S. Andrade1, R. Oliveira1, M.A. Vieira1, R. Minamisava2, V. Pessoa, Junior1, M.C.C. Brandileone*, 1Institute of Tropical Pathology and Public Health, Federal University of Goiás, Brazil, 2School of Nursing, Federal University of Goiás, Brazil, *Adolfo Lutz Institute, Brazil, *Wyeth Pharmaceuticals, Brazil, *Wyeth Pharmaceuticals, United States

P55 Identifying Potential Vaccination Innovations for Measles in Developing Countries: Horizon Scanning and Technical Assessment
T Hazlet1, P Gillard1, C Bauch2, S Kadiyala1, B Bresnahan1, L Garrison1, 1University of Washington Pharmaceutical Outcomes Research & Policy Program, United States, 2University of Gelph, Canada

P56 A phase 3 trial evaluating the safety, tolerability and immunogenicity of manufacturing scale 13-valent pneumococcal conjugate vaccine
J Gadzinowski1, S Tansey2, T Mellelieu2, S Baker2, PC Giardina2, PC Giardina2, DA Scott*, 1Univ. of Med. Sciences, Poland, 2Wyeth Vaccines Research, United Kingdom, 3Wyeth Vaccines Research, United States
P57 Recombinant baculoviruses as vehicles for presentation and adjuvancy of antigens for the development of new TB candidate vaccines
P. Molinari1, M.V. Bianco1, A. Peralta1, A.A. Cataldi1, F. Bigi1, O.A. Taboga1, 1 Institute of Biotecnology, INTA, Argentina

P58 Age-specific serum IgA anti-Salmonella enterica serovar Typhimurium immune response in Yucatán, Mexico
I Secundino1, M Fernández-Mora1, F Martínez2, JJ Calva3, MB Zaidi2, E Calva1, 1 UNAM, Mexico, 2 Hospital General O’Horan, Mexico, 3 INCMNSZ, Mexico

P59 Liposome in in situ gelling system: Novel Carrier Based Vaccine Adjuvant for Intranasal Delivery of Recombinant Antigen Vaccine
Shailja tiwari1, Amit Kumar Goyal1, Neeraj Mishra1, Bhuvaneshwar Vaidya1, Suresh Prasad Vyas1, 1 Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, Indi

P60 Invasive Pneumococcal Disease among Hospitalized Children in El Salvador. Seven years of Surveillance
Mario Antonio Gamero Rosalez1, Dilia Valencia1, 1 Hospital de Niños Benjamin Bloom, El Salvador

P61 Identification of leptospirosis sub-unit vaccine candidates
S R Felix1, E F da Silva1, S D D Jouglard1, D Hartmann1, O A Dellagostin1, 1 Universidade Federal de Pelotas, Brazil

X. Lenne1, D. Lévy-Bruhl2, Y. Kudjawu2, Y. Yazdanpanah3, J.C. Desenclos3, B. Dervaux1, 1 CRESGE/LEM, UMR CNRS 8179, Université Catholique de Lille, France, 2 Département des Maladies Infectieuses, InVS, France, 3 Service Universitaire des Maladies infectieuses et du voyageur, Centre hospitalier de Tourcoing, France

P63 Immunisation of Children from 0 to 5 Years in Cameroon, Bonassama Health District After An Outbreak of Poliomyelities in 2008 in a Nearby Health District
S N MBUNYA1, B A FOUDA1, M E EDENGUE1, 1 MINISTRY OF PUBLIC HEALTH, BONASSAMA HEALTH DISTRICT, Cameroon

P64 A mathematical model of the HPV-specific antibody production following immunization with a VLP-based vaccine
G. Olivera1, A.C. Jacquard2, B. Soubeyrand3, F. Gueyffier1, J.P. Boissel1, 1 The Institute for Theoretical Medicine, France, 2 Sanofi Pasteur MSD, France

P65 Immunization of mice with Lactobacillus casei expressing intimin fragments induces antibodies able to inhibit the adhesion of enteropathogenic Escherichia coli to cultivated epithelial cells
PCD Ferreira1, IB Campos1, CM Abe1, WP Elias1, PL Ho1, MLS Oliveira1, 1 Instituto Butantan, Brazil

P66 A synthetic peptide encompassing the G5 antigenic region of the rabies virus induces high avidity but poorly neutralizing antibody in immunized animals
Simone Niederhäuser1, Dorothy Brugger1, Marie-Luise Zahno1, Hans-Rudolf Vogt1, Ernst Peterhans1, Reto Zanoni1, 1 Institute of Veterinary Virology, Switzerland

P67 Screening the Schistosoma mansoni transcriptome for genes differentially expressed in the schistosoma stage in search for vaccine candidates
LP Farias1, CA Tararam1, PA Miyasato1, T Kawano1, S VerjoVski-Almeida2, LCC Leite1, 1 Instituto Butantan, Brazil, 2 University of São Paulo, Brazil

P68 Assessment of DNA Vaccination Strategies for Schistosomiasis Candidate Antigen, Sm-p80 in Mouse and Nonhuman Primate Models
G Ahmad1, W Torben1, R Damian2, R Kennedy1, R Wolf1, A Siddiqui1, 1 Texas Tech University Health Sciences Center, United States, 2 University of Georgia, United States, 3 University of Oklahoma Health Sciences Center, United States
A Probiotic Dairy Product Improves Antibody Responses to Influenza Vaccination in the Elderly

S VAUDAINE¹, R BOURED-SICARD¹, T BOGE¹, J TANGUY¹, S VAN DER WERF², SI SAMSON¹, ¹Danone Research, France, ²Pasteur Institute, France, ³Geriatrician, France

A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda SF+ cells

N. Bonafé¹, J.A. Rininger², R.G. Chubet², S. Fader¹, H.G. Foellmer³, J.F. Anderson⁴, Raymond Koski¹, ¹L2 Diagnostics, LLC, United States, ²Protein Sciences Corporation, United States, ³Yale University School of Medicine, United States, ⁴Agricultural Experiment Station, United States, ⁵University of Connecticut, United States

Newcastle Disease Virus-Like Particles as a Vaccine Platform

L W McGinnes¹, K Gravel¹, H Pantua¹, TG Morrison¹, ¹University of Massachusetts Medical School, United States

Rotavirus vaccination uptake and compliance among managed care infants in the United States (US)

A.R. Sklar¹, J.E. Kemner², H.J. Henk¹, ¹i3innovus, United States, ²GlaxoSmithKline, United States

2005-2007 Mumps outbreak in the Czech Republic.

R Prymula¹, C Benes², M Kubinyiova², J Castková², V Prikazsky², R Chlibek¹, ¹Faculty of Military Health Sciences, University of Defence, Czech Republic, ²National Institute of Public Health, Czech Republic

A vaccine candidate epitope anti-S. pyogenes associated with proteoliposome derived – cochleate adjuvant induces mucosal immune response in BALB/c mice.

L Guilherme¹, FT HIGA¹, E POSTOL¹, MT GUERINO¹, DS ROSA¹, SP RIBEIRO¹, ¹Heart Institute,School of Medicine University of Sao Paulo, Brazil, ²Clinical Immunology and Allergy, Department of Clinical Medicine; Medical School, University of Sao Paulo, Brazil, ³Immunology Department, Finlay Institute, Cuba

Anti-S pyogenes vaccine candidate epitope was evaluated by using HLA class II DR and DQ transgenic mice.

J Kalil¹,², E Postol¹, MT Guerino¹, FT Higa¹, LR Mundel¹, L Guilherme¹, ¹Heart Institute (InCor) School of Medicine; University of Sao Paulo, Brazil, ²Clinical Immunology and Allergy, Department of Clinical Medicine; Medical School, University of Sao Paulo, Brazil


A.J. Garcia Rojas¹, D Nuñez Gallo¹, M Naranjo Baez¹, ¹Epidemiology Service, Spain, ²Epidemiology Service, Spain, ³Public Health Service, Spain

Simulation model for comparing the costs and effectiveness of different pneumococcal conjugate vaccines

P De Wals¹, ¹Laval University, Canada

Tissue Vaccines for Prevention and Treatment of Prostate Cancer

M.A. Suckow¹, P. Hall², M.C. Hiles², ¹University of Notre Dame, United States, ²Cook Biotech, Inc., United States

Protection mediated by the Yersinia pestis F1-V plague vaccine in two animal models of plague: a contrast in immune response in murine and nonhuman primates.

K Amemiya¹, ¹US Army Medical Research Institute of Infectious Diseases, United States

Induction of specific and protective T-cell immune responses to HBsAg by the use of 1/01/0023.

Anamika Khajuria¹, Pankaj Suden¹, Tabasum Sidiq¹, Sarang Bani¹, K.A Suri¹, N.K Satti¹, ¹Indian Institute of Integrative Medicine, India

Screening Determines Monoclonal Specificity

K Jambunathan¹, H.M Geysen¹, ¹University of Virginia, United States
P82 Humoral and cellular immunity of dairy cattle one year after vaccination with a phase 1 Coxiella vaccine
A Rodolakis1, P Clement1, D Cochinneau1, R Guatteo2, P Sarradin3, F Beaudreau2, 1INRA UR 1282 IASP, France, 2ENVO-INRA UMR1300 BIEPAR, France, 3INRA UE 1277 PFIE, France

P83 Effector Function and Efficacy of CD8+ T Cells Activated in the Absence of IFN-γ
M.H. Nelson1, M.D. Bird2, C-F Chu1, G.N. Milligan1, 1University of Texas Medical Branch, United States, 2Loyola Medical Center, United States

P84 Effector CD4+ T lymphocytes resolve acute Herpes Simplex Virus (HSV)-1 infection in neural tissues
AJ Johnson1, C-F Chu1, GN Milligan1, 1University of Texas Medical Branch, United States

P85 New Perspectives and Models for Hepatitis B vaccines and Immunization
Maria Rapicetta1, 1Istituto Superiore di Sanità', Italy

P86 Strong and Specific Protective and Therapeutic Immunity Induced by Single HLA-A2.1 Restricted Epitope DNA Vaccine in Rabbits
JH Hu1, TS Schell1, XP Peng1, NMC Cladel1, KKB Balogh1, NDC Christensen1, 1Pennsylvania State University, United States

P87 Ferret Model of Avian Influenza Demonstrates Dose and Strain Dependant Pathology and Viral Load in Brain
RC Layton1, P Armijo1, L Myers1, J Knight1, 1Lovelace Respiratory Research Institute, United States, 2Ibis Biosciences, Inc., United States

P88 Intravitral Microscopic Characterization of the Innate Immune Responses to Influenza
S.F. Gonzalez2, M. Kuligowski1, L.A. Pitcher1, M.C. Carroll1, 1IDI Institute, Harvard Medical School, United States

P89 Mycobacterium Hsp65 DNA vaccine against murine model of Paracoccidioidomycosis
Alice Ribeiro1, A Bocc1, A Amaral1, F Facciol1, CL Elva1, CL Si1, 1University of Brasilia, Brazil, 2The Centre for Tuberculosis Research, University of Sào Paulo, Brazil, 3Catholic University of Brasilia, Brazil, 4Farmacore Biotecnologia, Brazil

P90 Induction of immune response to Salmonella Typhimurium by the OmpS1 porin
I Secundino1, E Calva1, 1UNAM, Mexico

P91 Oral therapeutic vaccination against dental caries in a rat model
Marcia D. Botelho Dinis1,2, Delfina Tavares1,2, Isabel Veiga-Malta1,2, António J.M.M. Fonseca1,2, Gabriela Trigo1,2, Elva Bonifácio Andrade1,2, 1ICBAS- Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Portugal, 2IBMC- Instituto de Biologia Molecular e Celular, Universidade do Porto, Portugal, 3Hospitais Universitários, Universidade de Coimbra, Portugal, 4Faculdade de Medicina, Universidade Coimbra, Portugal

P92 A Gag peptide encompassing B- and T- cell epitopes of the caprine arthritis encephalitis virus functions as modular carrier peptide
Simone Niederhäuser1, Celia Nensely1, Chiara Nenci1, Hans-Rudolf Vogt1, Reto Zanoni1, Ernst Peterhans1, 1Institute of Veterinary Virology, University of Bern, Switzerland

P93 Entecavir treatment combined with DNA vaccine and recombinant fowlpox virus “prime-boost” vaccination for chronic hepatitis B virus infection
Feng Feng1, Chee Quin Teoh2, David Boyle2, Allison Gilbert1, 1School of Molecular & Biomedical Science, University of Adelaide, Australia, 2CSIRO Livestock Industries, Australian Animal Health Laboratory, Australia

P94 Immunomodulation by Nisin of Interferon Gamma and LPS Activity on Murine Macrophages
L. Oliveira-Nascimento1, L.A.Jr Gerardi2, D.G. Mafra2, M.M. Borges2, A.F Jozala1, A. Pessoa Jr1, 1School of Pharmaceutical Sciences - USP, Brazil, 2Instituto Butantan, Brazil
P95 Implication of Arginase and TGF-beta in NO Synthesis by Macrophage Activated by Bordetella Pertussis
A.S. Rosetti1, J Abrahão Neto2, C.S. Galhardo1, M.A. Stephano2, I.A. Abrahamssohn3, M.M. Borges1, Instituto Butantan, Brazil, University of São Paulo, Brazil, Instituto de Ciencias Biomédicas, Brazil

P96 IL-12 Synthesis induced by Bordetella Pertussis and Parapertussis on Murine Macrophages
C.S. Galhardo1, A.S. Rosetti1, P. Iamashita1, L. Oliveira-Nascimento2, M.A. Stephano2, M.M. Borges1, Instituto Butantan, Brazil, School of Pharmaceutical Sciences, Brazil

P97 Development of immunization strategies against leishmaniosis based on the Leishmania histones pathoantigens
J CARRION1, C FOLGUEIRA1, C ALONSO1, Centro de Biología Molecular Severo Ochoa CSIC UAM, Spain

P98 Evaluation of Enzyme-Linked Immunosorbent Assays-Based on MPL17 and MPL21 Reombinant Leptospiral Antigens for Serodiagnosis of Leptospirosis
AL Nascimento1,2, TR Oliveira1, MT Longhi1, ZM Morais3, Instituto Butantan, Brazil, Interunidades Biotecnologia, Universidade de Sao Paulo, Brazil, Universidade de Sao Paulo, Brazil, Instituto Adolfo Lutz, Brazil, SUCEN, Brazil

P99 T-cell Vaccines that Elicit Effective Immune Responses against HCV in Chimpanzees Create Greater Immune Pressure for Viral Mutation
I Zubkova1, Y Choi2, E Chang3, K Pirollo3, H Krawczynski2, M Major1, CBER/Food and Drug Administration, United States, Centers for Disease Control and Prevention, United States, Georgetown University, United States

P100 Shigella sonnei oligosaccharide-protein conjugates.
J Kubler-Kielb1, E Vinogradov6, C Mocca1, R Schneerson1, NIH, United States, NRC, Canada

P101 Adjuvanted vaccine components: Analysis of structure and stability
M Kirkstadzde1, A Sinha1, J Hu1, W Williams1, G Cates1, Sanofi Pasteur Limited, Canada

P102 Expression of Avian Influenza Virus Epitope (M2e) in fusion with Potato Virus X Coat Protein
A. Natilla1, L.G. Nemchinov1, Molecular Plant Pathology Laboratory, Plant Sciences Institute, United States Department of Agriculture, Agricultural Research Service, United States

P103 Induction of anti-tumor immunity by the baculovirus Autographa californica multiple nuclear polyhedrosis virus
Hiroshi Takaku1, Takashi Ave1, Yoshiharu Matsuura1, Masayuki Kitajima1, Chiba Institute of Technology, Japan

P104 In vivo Delivery of Herpes Simplex Type 1 Glycoprotein B Confers Substantial Protection against Genital Herpes
M Pistello1, L Vannucci1, F Chiuppesi1, B Matteoli1, R Manservigi2, M Bendinelli1, Retrovirus Center and Virology Section, Department of Experimental Pathology, University of Pisa, Pisa, Italy, Department of Experimental Medicine and Diagnostic, University of Ferrara, Ferrara, Italy

P105 Molecular Epidemiology of Varicella-Zoster Virus Isolated from Herpes Zoster Patients in Vaccination Era
Kye-Hyung Kim1, Young Ju Choi1, Kyoung-Ho Song1, Shinwon Lee1, Hee-Chang Jang1, Jae Hyun Jeon1, Department of Internal Medicine, Seoul National University College of Medicine, Korea, Republic of

P106 Correlating Early B Cell Responses With Long Term Protection: Towards A Fast Screening Assay For Vaccine Candidates
W. Wieland1, J. Sijtsma1, R. Boshuizen2, W. van Eden1, R.H. Meloen2, R. van der Zee1, Utrecht University, Netherlands, Pepscan, Netherlands
P107 Construction and characterization of mutant Dengue2 virus vaccine candidates displaying a host-range phenotype  
K.M. Smith¹, K. Nanda², C. J. Slominski³, R. Hernandez², D. T. Brown², M. E. Thomas¹,  
¹Arbovax, Inc., Raleigh, NC, United States; ²North Carolina State University, Department of  
Molecular and Structural Biochemistry, Raleigh, NC, United States

P108 The immune efficiency of a bivalent virus-like particle vaccine for human  
papillomavirus types 16 and 11  
Hongxi Gu¹, Lanlan Wei¹, Ming Zhuant¹, Zhaohua Zhong¹,  
¹Department of Microbiology, China

P109 Identification and Development of a Promising Novel Mumps Vaccine  
Candidate Strain  
Yan Liang¹, Shaohui Ma¹, Longding Liu¹, Lichun Wang¹, Li Jiang¹, Qihan Li¹,  
¹Institute of medical biology, China

P110 Immunogenic assay of one enterovirus 71 strain isolated during Epidemic in  
China and its adapting in fibroblast cell culture use as a vaccine candidate  
Longding Liu¹, Shaohui Ma¹, Jiansheng Liu¹, Qihan Li¹,  
¹Institute of medical biology, China

P111 Rotavirus A genotypes circulating before and after the implementation of the  
monovalent vaccine in Rio de Janeiro, Brazil.  
FA Carvalho Costa¹, IT Araujo¹, RMS Assis¹, AM Fialho¹, MN Bóia³,  
³Laboratory of Comparative Virology, Oswaldo Cruz Institute, Brazil; ²Salles Neto Municipal Hospital,  
Brazil; ¹Institute of Parasitic Diseases, Oswaldo Cruz Institute, Brazil

P112 Safety and Tolerability of 3 lots of 13-valent Pneumococcal Conjugate Vaccine  
in Healthy Infants Given With Routine Pediatric Vaccinations in the USA  
T Payton¹, DA Scott¹,², S Patterson¹,², A Razmpour¹,², D Girgenti¹,²,  
¹Northwest Arkansas Pediatrics, Fayetteville, AR, United States; ²Wyeth Vaccines Research, Pearl River, NY,  
United States; ³Wyeth Research, Collegeville, PA, United States

P113 Concentration and purification of influenza viruses by sulfate ester of cellulose  
(Cellufine Sulfate®)  
Kouichi Ozaki¹, Yasuto Umeda², Shigeyuki Aoyama², Norikazu Isoda¹, Masatoshi Okamatsu¹,  
Yoshihiro Sakoda¹, ²Graduate School of Veterinary Medicine, Hokkaido University, Japan;  
³Chisso Corporation, Japan

P114 The Comparative Evaluation of Expanded National Immunization Policies in  
Korea Using an Analytic Hierarchy Process  
T Shin¹, CB Kim², YH Ahn², HY Kim², BH Cha², Y Uh²,  
¹College of Government & Business, Yonsei University, Korea, Republic of; ²Yonsei University Wonju College of Medicine, Korea, Republic of

P115 Reactogenicity of MenACWY-CRM administered sequentially or concomitantly  
with Tdap and HPV vaccines  
A Arguedas¹, C Soley¹, C Loaiza¹, G Rincon¹, S Guevara¹, A Perez¹,  
¹Instituto de Atención Pediátrica San José, Costa Rica; ²Novartis Vaccines and Diagnostics, Inc., Emeryville, CA,  
United States; ³Novartis Vaccines and Diagnostics, Inc., Cambridge, MA, United States

P116 Bioinformatics prediction combined with synthesized peptides reveal an  
antigenic determinant of a membrane protein of LCDV-cn  
S.Q. Wu¹, X.Q. Sun¹, J.X. Zhang¹, F.R. Zheng¹,  
¹First Institute of Oceanography, the State Oceanic Administration, China

P117 Safety and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine  
Given Concomitantly with Trivalent Inactivated Influenza Vaccine in Healthy Adults  
TF SCHWARZ¹, J FLAMAING², HC RUMKE³, J J PENZES¹, C JUERGENS², A WENZ³,  
¹Stiftung Juliusstift Wuerzburg, Germany; ²Dept of Geriatric Medicine, Univ Hospital Leuven,  
Belgium; ³Vaxinistics, Rotterdam, Netherlands; ⁴Konszenzus Pluzs Kft, Csongrád, Hungary;  
⁵Wyeth Research, Muenster, Germany; ⁶Wyeth Vaccines Research, Pearl River, NY, United States;  
⁷Wyeth Research, Collegeville, PA, United States
P118  Hepatitis B surface antigen-specific T cell memory in health care workers who have lost anti-HBs antibodies after hepatitis B vaccination over a period of time
Anuradha Tripathy¹, Mandeep Chadha¹, Rumki Das¹, Vidya Arankalle¹, ¹National Institute of Virology, India

P119  Mucosal immunisation against PBP2a reduces MRSA nasal colonisation in mice.
J.M.P. Senna¹, S. Guoussard¹, C. Grillo-Courvalin¹, ¹Fiocruz (Fundação Oswaldo Cruz) - Bio-Manguinhos, Brazil, ²Institut Pasteur, France, ³Institut Pasteur, France

P120  Vaccination among University Students: The Role of Parental Educational Attainment in Sustaining Vaccination Disparities
Gregory Cherkowski¹, Arnold Monto¹, Monica Uddin¹, Rebecca Coulborn¹, Allison Aiello¹, ¹University of Michigan School of Public Health, United States

P121  Withdrawn

P122  Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis
M Pavia¹, A Bianco¹, P Marinelli², IF Angelillo², P Crovari², ¹Chair of Hygiene, Medical School, University of Catanzaro "Magna Graecia", Italy, ²Department of Public, Clinical and Preventive Medicine, Second University of Naples, Italy

P123  Impact of varicella vaccination coverage upon varicella-related hospitalizations in France and Germany: projections from a dynamic transmission model
T Van Effelterre¹, C Hogue², C Cohen¹, ¹GlaxoSmithKline Biologicals, Rixensart, Belgium, ²GlaxoSmithKline Biologicals, Philadelphia, United States

P124  New Approaches for the Analysis of Bacterial Surface Exposed Proteins
N Norais¹, F Berlanda Scorza¹, M Biagini¹, F Doro¹, S Liberatori¹, I Margarit¹, ¹Novartis Vaccines Diagnostics, Italy

P125  Rapid Development and Validation of a T-Cell Epitope-Based Tularemia Vaccine for F. Tularensis
A DeGroot¹,², L Moise¹,², W Martin¹, J Desrosiers¹, J McMurry¹, ¹EpiVax, Inc., Providence RI, United States, ²University of Rhode Island, United States, ³Brown University, Providence, RI, United States

P126  A “Venn” Vaccine: Selection and Validation of Vaccinia-Variola-Conserved Epitopes
L Moise¹,², A De Groot¹,², J McMurry², J Desrosiers², R Tassone², W Martin², ¹Institute for Immunology and Informatics, University of Rhode Island, Providence, RI, United States, ²EpiVax, Providence, RI, United States, ³U. Mass Medical School, Worcester, MA, United States, ⁴Saint Louis University, Saint Louis, MO, United States

P127  The Gaia HIV Vaccine Progress Report: Broad Recognition of Class I and II Restricted Epitopes and In Vivo Studies
A De Groot¹,², L Shuo¹, J Desrosiers¹, R Tassone¹, W Martin¹, K Coulibaly², ¹EpiVax, Providence, RI, United States, ²Faculté de Sciences et Technologie, Bamako, Mali, ³Institute for Immunology and Informatics, Providence, RI, United States

P128  Role of Tregs: Insights for the design of improved Hepatitis C vaccine
A De Groot⁶, L Shuo³, S Floess³, G Silvana³, A Lucas³, A Hamann⁴, ¹Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia, Australia, ²EpiVax, Inc. Providence RI USA, United States, ³Experimental Rheumatology, Charite’ University Medicine Berlin, Germany, Germany, ⁴Centre for Clinical Immunology and Biomedical Statistics, Perth, Western Australia, Australia

P129  Effect of Maternal Antibodies on Infant Pertussis Vaccination
Monika Polewicz¹, Anastasia Njinik¹, Robert E.W. Hancock², Lorne Babiuk¹, Scott Halperin³, Volker Gerdt³, ¹VIDO, University of Saskatchewan, Canada, ²Centre for Microbial Diseases and Immunity Research, Canada, ³Canadian Center for Vaccinology, Canada
P130  Recombinant Alphavirus Replicons as a Potential Screening Approach to Evaluate Immunogenicity of Newly Designed HIV Vaccine Envelopes
Michael Franti¹, Indresh Srivastava¹, Susan Barnett¹, ¹Novartis Vaccines and Diagnostic, Inc, United States, ²Regional Primate Center, UC Davis., United States

P131  Bicistronic Plasmid Approach for DNA Vaccine Development Against African Trypanosomiasis
MS Silva¹, E Martinez-Salas², AS Lança¹, KP De Sousa¹, C Ferrão¹, GA Monteiro¹, ¹Center for Malaria and Tropical Diseases - Institute of Hygiene and Tropical Medicine. Lisbon, Portugal, ²Centro de Biologia Molecular Severo Ochoa - Universidad Autonoma de Madrid. Madrid, Spain, ³Institute for Biotechnology and Bioengineering - Instituto Superior Técnico. Lisbon, Portugal

P132  Structure based rational design of HIV Env immunogens for vaccine development
IK Srivastva¹, K Hartog¹, Zohar Biron¹, E Kan¹, Yi DE Sun¹, Y Lian¹, ¹Novartis Vaccines and Diagnostics, Inc.,Cambridge, MA, United States, ²Novartis Vaccines and Dianostics, Inc., Siena, Italy

P133  EpiMatrix: Tool for Accelerated Epitope Selection and Vaccine Design
M Ardito¹, A De Groot¹, J McMurry¹, L Moise¹, W Yang¹, B Martin¹, ¹EpiVax, Inc. Providence RI, United States, ²Institute for Immunology and Informatics, University of Rhode Island, United States

P134  Immunoprophylactic Activity of a CpG-Containing Immunogen on the Development of Experimental Respiratory Allergy to Blomia Tropicalis
David Andrade¹, Tassia Lopes¹, Virginia Silva¹, Neuza Neves², Lain Carvalho¹, ¹Centro de Pesquisa Gonçalo Moniz - FIOCRUZ, Brazil, ²Universidade Federal da Bahia, Brazil

P135  Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-g and cytolytic activity by CD8+ T cells
Ana Paula Fernandes¹, Daniela Resende¹, Bráulia Caetano¹, Miriam Dutra¹, Marcus Penido¹, Christiane de Abrantes², ¹Federal University of Minas Gerais, Brazil, ²Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States

P136  Protective immunity against challenge with Leishmania chagasi in susceptible beagle dogs vaccinated with recombinant A2 protein
Ana Paula Fernandes¹, Miriam Silva Costa¹, Eduardo Ferraz Coelho¹, Marlene Michalick³, Eloisa de Freitas¹, Wagner Tafuri¹, ¹Federal University of Minas Gerais – Belo Horizonte, MG, Brazil, ²Rene Rachou Institute, Oswaldo Cruz Foundation – Belo Horizonte, MG, Brazil, ³Hertape Calier Saude Animal, Brazil

P137  Immunity against porcine circovirus 2 by vaccination with ORF2-based DNA in mice
Ji-Yong Zhou¹,², Hui-Gang Shen¹,², Zhen-Yu Huang¹,², Jun-Qing Guo¹,², Gang Xing¹,², Jia-Ling He¹,², ¹Key Laboratory of Animal Epidemic Etiology & Immune control of Ministry of Agriculture, Institute of Preventive Veterinary Medicine, Zhejiang University, China, ²State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University, Hangzhou 310029, China

P138  Recombinant alphavirus and adjuvanted protein vaccines delivered mucosally and systemically protect macaques from mucosal SHIV challenges
SW Barnett¹, M Vajdy¹, B Burke¹, J zur Megede¹, E Kan¹, Y Lian¹, ¹Novartis Vaccines and Diagnostics, Inc., Cambridge, MA, United States, ²Novartis Vaccines and Diagnostics, Inc., Siena, Italy
P139 In vitro expression and bioactivity of duck interleukin-2
Ji-Yong Zhou1, Jin-Yong Wang1, Ji-Gang Chen1, Key Laboratory of Animal Epidemic Etiology & Immune control of Ministry of Agriculture, Institute of Preventive Veterinary Medicine, Zhejiang University, Hangzhou 310029, China

P140 Production and characterization of monoclonal antibody to duck CD8α
ZY Huang1,2, JY Gu1,2, QY Teng1,2, HB Li1,2, JQ Guo1,2, JY Zhou1,2, Key Laboratory of Animal Epidemic Etiology & Immune control of Ministry of Agriculture, Institute of Preventive Veterinary Medicine, Zhejiang University, Hangzhou 310029, China

P141 The molecular mechanism of attenuation for IBDV NB strain passaged on CEF
Lixue Shi1,2, Haibin Li1,2, Guangpeng Ma1,2, Jiyong Zhou1,2, Lianlian Hong1,2, Xiaojian Zheng1, Key Laboratory of Animal Epidemic Etiology & Immune control of Ministry of Agriculture, China, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, China, China Rural Technology Development Center, China

P142 Transcription analysis and prokaryotic expression of chicken IL-2 receptor gamma chain gene
Gu Jianyou1, Teng Qiaoyang1, Wang Zhenyu1, Zhou Jiyoung1, Institute of Preventive Veterinary Medicine, China

P143 In vitro anti-viral activity of serum from mice immunized with liposomes containing the M2 ectodomain (M2e) of the influenza virus
W. Ernst1, M. Munoz2, H. Kim3, G. Fujii1, J. Adler-Moore4, B Mothé5, Molecular Express, Inc., United States, California State Polytechnic University, Pomona, United States

P144 Immunological Characterization of Liposomal HSV2 gD fusion protein in BALB/c Mice
J. Adler-Moore5, K. Olson1, P. Macias1, W. Ernst2, G. Fujii2, Molecular Express, Inc., United States

P145 Factors associated with Pneumococcal immunization among hospitalised elderly persons: A survey of patient’s perception, attitude, and knowledge
LR Ridd1,2, RI Lindley1,2, PB McIntyre1,2, CR MacIntyre1,2, National Centre for Immunisation Research and Surveillance, The University of Sydney, Australia, Discipline of Medicine: Geriatric Medicine. The University of Sydney, Australia, Discipline of Paediatrics and Child Health. The University of Sydney, Australia, School of Public Health and Community Medicine. The University of New South Wales, Australia

P146 Differences in attitudes, beliefs and knowledge of hospital health care workers and community doctors to vaccination of older people
LR Ridd1,2, RI Lindley1,2, Z Gao1,2, P McIntyre1,2, CR MacIntyre1,2, National Centre for Immunisation Research and Surveillance, The University of Sydney, Australia, Discipline of Medicine: Geriatric Medicine. The University of Sydney, Australia, School of Public Health and Community Medicine. The University of New South Wales, Australia

P147 The benefit of molecular characterization during a measles upsurge in Denmark
M. Muscat1, L. Vinner2, A.H. Christiansen1, S. Glismann1, B.E. Böttiger2, Department of Epidemiology, Statens Serum Institut, Denmark, Department of Virology, Statens Serum Institut, Denmark

P148 Measles hotspots in Europe
M Muscat1, H Bang1, J Wolfsfahrt1, S Glismann1, K Mølbak1, EUVAC.NET group3, Department of Epidemiology, Statens Serum Institut, Denmark, Department of Epidemiology Research, Statens Serum Institut, Denmark, European public health and surveillance institutions,............

P149 Selecting Staphylococcus aureus vaccine candidates
Fabio Bagnoli1, Luigi Fiaschi1, Masimiliano Biagini1, Nathalie Norais1, Maria Scarselli1, Francesco Doro1, Ilaria Ferlenghi1, Claudio Donati1, Rino Rappuoli1, Guido Grandi1, Novartis Vaccines and Diagnostics, Italy
P150  Nasal Delivery of an Ebola Adenovirus-Based Vaccine Bypasses Pre-existing Immunity to the Vaccine Carrier
Maria Croyle¹, Mickey Sahib¹,², Ami Patel²,³, Kaylie Tran³, Michael Gray³, Yi Zhang⁴, James Strong⁴, Heinz Feldmann⁵, Gary Kobinger⁶, ¹The University of Texas at Austin, United States, ²Public Health Agency of Canada, Canada, ³University of Manitoba, Canada, ⁴University of Michigan, United States

P151  Global HIV Vaccine Research Cryorepository - GHRC
H. von Briesen¹, E. M. Fenyö², H. Holmes³, E. V. Karamov⁴, A. Meyerhans⁵, M. Morgado⁶, ¹Fraunhofer IBMT, Germany, ²University of Lund, Sweden, ³NIBSC, United Kingdom, ⁴Ivanovski Institut, Russian Federation, ⁵University of Saarland, Germany, ⁶WHO, Switzerland, ⁷Stellenbosch University, South Africa, ⁸Fondazione San Raffaele, Italy, ⁹NIH, United States, ¹⁰Siriraj Hospital, Thailand

P152  Development of the auxotropic selection marker and production technology for the DNA plasmid based genetic vaccine vectors.
M. Ustav¹,², T. Tenson³, K. Reijonen², U. Toots¹, T. Kärkkäinen², A. Männik¹, ¹FIT Biotech Oy Eesti AS, Estonia, ²FIT Biotech Oy, Finland, ³Institute of Technology, University of Tartu, Estonia

P153  A Network for Supporting Vaccine Development in Europe
TJG Brooks¹, JM Duggan¹, BAM van der Zeijst², J Hendriks³, ¹Health Protection Agency, United Kingdom, ²Netherlands Vaccine Institute, Netherlands

P154  Towards a Global Vaccine Safety Datalink: Rationale, Available Infrastructure Globally and Progress to Date.
S.B. Black¹, ¹Center for Global Child Health, Cincinnati Childrens' Hospital, United States

P155  Cationic bilayer fragments as immunoadjuvants
N. Lincopan¹, N.M. Espíndola¹, A.J. Vaz¹, A.M. Carmona-Ribeiro¹, ¹Universidade de São Paulo, Brazil

P156  Silica-based cationic bilayers as immunoadjuvants
N. Lincopan¹, M.R.A. Santana¹, M.H.B. Costa², E.L. Faquim-Mauro², A.M. Carmona-Ribeiro¹, ¹Universidade de São Paulo, Brazil, ²Instituto Butantan, Brazil

P157  Genetic interaction of vaccinia virus with cells and its oncological safety
A.D. Altstein¹, N.F. Grinenko¹, L.G. Zakharova¹, L.M. Piskareva¹, G.V. Pashvykina¹, ¹Institute of Gene Biology, Russian Federation

P158  Induction of Immune Response of Hepatitis B Vaccine Using PolyesterPolymer as an Adjuvant
S M SIVAKUMAR¹, N SUKUMARAN¹,², ¹Division of Research and Development, Nehru College of Pharmacy, India, ²Sri Paramakalyani Centre for Environmental Sciences, India

P159  An Immunoregulatory Role for Cyclooxygenase-2 in Human B Lymphocytes Stimulated with CpG Oligodeoxynucleotides: Implications for Vaccination
M.P. Bernard¹, R.P. Phipps¹, ¹University of Rochester School of Medicine and Dentistry, United States

P160  Biodegradable Polymeric Nanoparticles as Vaccine Delivery Systems
S.A. Ferreira¹, P.M. Gama¹, ¹IBB-Institute for Biotechnology and Bioengineering, Centre for Biological, Portugal

P161  Effect of combination adjuvants composed of aluminium salts and TLR4 agonists on the immune response
A. Sokolovska¹, H. HogenEsch¹, ¹Purdue University, United States

P162  Effect of the dose of aluminum adjuvants on the immune response
K.M. Anderson¹, H. HogenEsch¹, ¹Purdue University, United States
P163 Effective induction of anti-tumor immune responses with oligomannose-coated liposomes targeting to intraperitoneal macrophages
K Tsujimura, Y Ikehara, T Nagata, Y Koide, N Kojima, Hamamatsu University School of Medicine, Japan, National Institute of Advanced Industrial Science and Technology, Japan, Tokai University, Japan.

P164 The Use of Soluble Trimers of African Horsesickness- or Bluetongue Virus VP7 as a Display Vector for Presenting Immunologically Important Peptides to the Immune System
QC Meyer, D Rutkowska, W Fick, W Vosloo, H Huismans, University of Pretoria, South Africa, Onderstepoort Veterinary Institute, South Africa.

P165 Use Of Alphavirus Replicons Expressing IL-12 As Highly Potent Vaccine Adjuvants

P166 Nanoparticle Based Combinatorial TLR Ligand Delivery Mediates Synergistic Immune Responses
Sudhir Pai Kasturi, Marcin Kwissa, Michael Heffernan, Niren Murthy, Bali Pulendran, Emory University, United States, Georgia Institute of Technology, United States.

P167 4-1BB Costimulation as an Adjuvant for HIV-1 DNA Vaccine: Different Effects by Anti-4-1BB Agonist Ab and 4-1BBL DNA
S Ganguly, J Liu, R Mittler, R Amara, Emory University, United States.

P168 Japanese Encephalitis Virus DNA Vaccine Using The Transcutaneous Immunization By Chitosan Complexes
Chang-Jer Wu, Hang-Ning Huang, Department of Food Science, National Taiwan Ocean University, Taiwan.

Mario Barro, Daniel Tonkin, Nancy Davis, Ande West, Linda Fritts, Chris Miller, Clayton Beard, Robert Johnston, Global Vaccines Inc, United States, Carolina Vaccine Institute at UNC, United States, California National Primate Research Center at UC Davis, United Kingdom.

P170 Bacillus subtilis as Particulate Adjuvant for Rabies Animal Vaccine
MA Stephang, Butantan Institute, Brazil, Sao Paulo University, Brazil.

P171 Sequential delivery of different cytokine genes as a novel adjuvant “prime-boost” strategy to enhance immune responses and CD4+ T memory cells
B Wang, B Su, Y Kang, China Agricultural University, China.

P172 Potent Adjuvant Formula Conferred by Triple Synergism Consisting of CpG, CL097, and MDP
J Lee, A Dhamko, H Komfeld, Umass Med, United States.

P173 Vaxfectin®, a Cationic Lipid-based Adjuvant for Protein-based Influenza Vaccines

P174 Analysis of Biomarkers after Intramuscular Injection of Vaxfectin®-formulated Antigens in Mice
M Shlapobersky, Q Wei, J Hartikka, S Sullivan, Vilalta, Vical Inc., United States.
P175 Decrease of CD4/CD25 T cell and increase of IFN-gamma in dog vaccinated with Leishmune an endemic area for visceral leishmaniasis
Valéria Lima¹, Fabiana Ikeda¹, Mary Feltoza¹, Rosimere Vasconcelos³, Cáris Nunes², Hiro Goto⁴, ¹Universidade Estadual Paulista- Faculdade de Odontologia- Departamento de Clínica, Cirurgia e Reprodução Animal, Brazil, ²Universidade Estadual Paulista- Faculdade de Odontologia- Departamento de Apoio Produção e Saúde, Brazil, ³Universidade Estadual Paulista- Faculdade de Ciências Agrárias e Veterinárias- Departamento de Patologia, Brazil, ⁴Universidade de São Paulo - Faculdade de Medicina - Departamento de Medicina Preventiva, Brazil

P176 Characterization of Tly proteins of Leptospira revealed that TlyC is an ECM binding protein but it is not a protective antigen against leptospirosis.
E. Carvalho¹,², A.S. Barbosa¹, R.M. Gómez³, E.C. Romero⁴, S.A. Vasconcellos⁵, P.L. Ho¹, ¹Instituto Butantan, Brazil, ²Instituto de Biociências da USP, Brazil, ³CONICET-UNLP, Argentina, ⁴Instituto Adolpho Lutz, Brazil, ⁵Faculdade de Medicina Veterinária e Zootecnia da USP, Brazil

P177 Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis (CVL)
GP Borja-Cabrera¹, FB Santos¹, E Picillo², AE Gravino², L Manna², CB Palatnik-de-Sousa¹, ¹Federal University of Rio de Janeiro, Brazil, ²Universita di napoli Federico II, Italy

P178 The Nucleoside hydrolase DNA vaccine VR1012NH36 in prophylactic vaccination against mice tegumentar leishmaniasis
LOP Souza¹, CB Palatnik-de-Sousa¹, ¹Federal University of Rio de Janeiro, Brazil

P179 The FML-vaccine against canine visceral leishmaniasis: from the second generation to the synthetic vaccine.
CB Palatnik-de-Sousa¹, ¹Federal University of Rio de Janeiro, Brazil

P180 Cloning of the Nucleoside hydrolase of Leishmania donovani aiming the development of a synthetic vaccine against visceral leishmaniasis
D Nico¹, C Claser², I Soares³, MM Rodrigues³, CB Palatnik-de-Sousa¹, ¹Federal University of Rio de Janeiro, Brazil, ²UNIFESP-Cintergen, Brazil, ³USP, Brazil

P181 A New Subunit Vaccine Based on Nucleocapsid Protein Nanoparticles Confers Partial Protection in Calves Against Respiratory Syncytial Virus
S Riffault¹, G Durand¹, M Soulestin², C Dubuquoy¹, M Deplanche², N Castagné¹, ¹UR892 INRA, France, ²UMR 1225 INRA-ENVT, France, ³UE1277 INRA, France, ⁴SEPPIC, Air Liquide, France

P182 How to implement vaccination against Coxiella burnetii infection in infected dairy herds?
F. Beaudeau¹, R. Guatteo¹, A. Rodolakis², H. Seegers¹, ¹Ecole Vétérinaire-INRA, UMR 1300 BioEpAR, France, ²INRA, UR 1282 IASP, France

P183 Priming of a mucosal response following parenteral DNA vaccination in pigs?
V Melkebeek¹, E Cox¹, BM Goddeeris¹, ¹Ghent University, Laboratory of Veterinary Immunology, Belgium

P184 Safety and immune responses in Guinea pigs and Pigs immunized with an inactivated vaccine containing three subtypes of swine influenza virus (H1N1, H1N2, H3N2) and Mycoplana hyopneumonia
DS Song¹, CS Lee¹, BK Park², BK Kang¹, ¹Green Cross Veterinary Products, Korea, Republic of, ²Department of Veterinary Medicine Virology Lab, College of Veterinary Medicine, Seoul National University, Korea, Republic of

P185 Efficacy of Live attenuated and Inactivated Oil Emulsion Infectious Bursal Disease Virus Vaccines in Broiler
NAZIR AHMAD¹, SHAFAQAT FATIMA¹, SHAHANA KAZMI¹, ¹UNIVERSITY OF KARACHI AND SINDH POULTRY VACCINE CENTRE, Pakistan
P186  An acellular vaccine delivered in microparticles confers protection against 
*Brucella ovis* infection in rams  
C Gamazo¹, R Martins², JM Blasco³, MP Muñoz³, CM Marín³, MJ Grilló³, ¹Dpt. Microbiology.  
University of Navarra, Spain, ²Dpt. Pharmacy. University of Navarra, Spain, ³SIA-DGA, Spain

P187  Adjuvant formulation for veterinary vaccines: Montanide™ Gel safety profile.  
SD Deville¹, AL Laval², RP Parker³, FB Bertrand¹, LD Dupuis¹, JA Aucouturier¹, ¹SEPPIC,  
France, ²ENVN, France, ³SEPPIC Inc, United States

P188  Identification of Marek’s Disease Virus Genes Mutated During Serial Passage- 
Induced Attenuation  
SJ Spatz¹, IM Gimeno², M Heidari³, ¹USDA ARS Southeast Poultry Research Laboratory,  
United States, ²North Carolina State University, United States, ³USDA ARS Avian Disease and Oncology Laboratory, Germany

P189  An IPNV oral vaccine using VP2 sub-viral particles (sVLP) and display of 
human oncogene c-myc marker on sVLP.  
Arun Dhar¹, Robert Bowers¹, Christopher Rowe¹, Vikram Vakaria², Scott LaPatra³, Franklin 
Allnutt¹, ¹Advanced BioNutrition Corp., United States, ²University of Maryland, United States, ³Clear Springs Food, Inc., United States

P190  Oral vaccination of Atlantic Salmon *Salmo salar* against Salmonid rickettsial 
septicaemia (SRS).  
Jamie Tobar¹, Tommy Jakovljevic¹, Paula Aedo¹, Moti Harel², Arun Dhar², Thomas 
Goodrich¹, ¹Laboratorios Centrovet, Chile, ²Advanced BioNutrition Corp, United States

P191  Design of a multi-epitope vaccine against Staphylococcus aureus  
M JOLOIS¹, B TAMINIAU¹, N RHAZI¹, A JACQUET², E HEINEN¹, ¹University of Liège,  
Belgium, ²Free University of Brussels, Belgium

P192  Restriction Fragment Length Polymorphism of Pakistani Field Isolates of 
Infectious Bursal Disease Virus (IBDV)  
NAZIR AHMAD¹, SHAFAQAT REHMANI¹, SHAHANA KAZMI¹, ¹DEPARTMENT OF 
MICROBIOLOGY, UNIVERSITY OF KARACHI, Pakistan